Ionis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2017
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Ionis Pharma (IONS) Q3 Revenue Tops Views
November 7, 2017 7:05 AM ESTIonis Pharma (NASDAQ: IONS) reported Q3 EPS of $0.00, $0.01 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $120.9 million versus the consensus estimate of $116.96 million.
For earnings history and earnings-related data on Ionis Pharma (IONS) click here.
... More